|
Jun 15
|
Arcutis Biotherapeutics (ARQT) Announces Enrolling the First Child in Phase 2 Trials
|
|
Jun 11
|
First child enrolled in Arcutis’ Phase II trial of cream for atopic dermatitis
|
|
Jun 10
|
Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
|
|
Apr 17
|
Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025
|
|
Apr 10
|
Arcutis Announces Chief Financial Officer Transition
|
|
Apr 3
|
Arcutis Biotherapeutics (ARQT) Moves 10.8% Higher: Will This Strength Last?
|
|
Apr 3
|
Why Arcutis Biotherapeutics Inc. (ARQT) Went Up On Wednesday?
|
|
Apr 2
|
Sector Update: Health Care Stocks Advance in Late Afternoon Trading
|
|
Apr 2
|
Arcutis and Padagis Agree to Stay Patent Lawsuit
|
|
Jan 16
|
Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 37.43%: Here's is How to Trade
|
|
Jan 3
|
Here's Why Arcutis Stock More Than Doubled in Market Value in One Year
|
|
Oct 25
|
Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
|
|
Oct 24
|
Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting
|
|
Oct 23
|
Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference
|
|
Oct 21
|
Health Canada approves Arcutis’ ZORYVE foam for seborrheic dermatitis
|
|
Oct 21
|
Arcutis Canada Announces Health Canada Approval of ZORYVE® Foam to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
|
|
Oct 3
|
Exploring High Growth Tech Stocks In The US October 2024
|
|
Sep 25
|
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types
|
|
Sep 24
|
FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
|
|
Aug 28
|
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
|